Virtu KCG Holdings LLC acquired a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 34,977 shares of the biotechnology company’s stock, valued at approximately $186,000. Virtu KCG Holdings LLC owned 0.08% of Anavex Life Sciences Corp. at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of AVXL. JPMorgan Chase & Co. acquired a new position in shares of Anavex Life Sciences Corp. in the first quarter worth approximately $105,000. Northwest Investment Counselors LLC acquired a new position in shares of Anavex Life Sciences Corp. in the second quarter worth approximately $106,000. American International Group Inc. lifted its stake in shares of Anavex Life Sciences Corp. by 7.1% in the first quarter. American International Group Inc. now owns 20,103 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 1,329 shares during the period. State of Wisconsin Investment Board acquired a new position in shares of Anavex Life Sciences Corp. in the second quarter worth approximately $151,000. Finally, Alliancebernstein L.P. acquired a new position in shares of Anavex Life Sciences Corp. in the second quarter worth approximately $158,000. 24.24% of the stock is currently owned by institutional investors.

A number of equities analysts recently commented on the company. Maxim Group set a $15.00 price objective on Anavex Life Sciences Corp. and gave the stock a “buy” rating in a research note on Thursday, October 12th. Noble Financial reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Anavex Life Sciences Corp. in a research note on Friday, September 29th. ValuEngine downgraded Anavex Life Sciences Corp. from a “hold” rating to a “sell” rating in a report on Thursday, September 28th. Finally, Zacks Investment Research upgraded Anavex Life Sciences Corp. from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Tuesday, September 26th.

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) opened at 4.18 on Friday. The firm has a 50-day moving average price of $4.33 and a 200-day moving average price of $4.33. The company’s market capitalization is $176.28 million. Anavex Life Sciences Corp. has a one year low of $2.76 and a one year high of $6.30.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Equities analysts forecast that Anavex Life Sciences Corp. will post ($0.37) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This article was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://theolympiareport.com/2017/10/29/34977-shares-in-anavex-life-sciences-corp-avxl-purchased-by-virtu-kcg-holdings-llc.html.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXL).

Institutional Ownership by Quarter for Anavex Life Sciences Corp. (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.